On November 9, 2021 Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that it will present six posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting, to be held in Washington, D.C. and virtually between November 10-14th (Press release, Immunocore, NOV 9, 2021, View Source [SID1234594868]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present a Phase 1b study of tebentafusp in combination with durvalumab (anti-PDL1) and/or tremelimumab (anti-CTLA4) in metastatic cutaneous melanoma (mCM) and new clinical data analyzing gene expression and overall survival from the metastatic uveal melanoma (mUM) tebentafusp monotherapy program. Four additional posters depicting new analyses from tebentafusp in metastatic uveal melanoma, as well as the Company’s proprietary soluble TCR bispecific ImmTAC platform will be made available for on-demand viewing throughout the SITC (Free SITC Whitepaper) 36th Annual Meeting on the SITC (Free SITC Whitepaper) website.

In a phase 1b trial in mCM of tebentafusp in combination with checkpoint inhibitors, in which the majority of patients had previously received prior anti-PD(L)1 therapy, the maximum target doses of tebentafusp (68 mcg) plus durvalumab (20 mg/kg) with and with/out tremelimumab (1 mg/kg) were tolerated in both doublet and triplet arms of the study. Preliminary evidence of tebentafusp clinical activity in mCM patients who received prior anti-PD(L)1 therapy, currently an unmet medical need, included 1-year overall survival (OS) rate of 76%. In mCM patients who were refractory (defined as best response of progressive disease) to prior anti-PD(L)1, the 1-year OS rate was 61%.

"At SITC (Free SITC Whitepaper), we build upon our previously released survival data in metastatic uveal melanoma with the clinical results of tebentafusp in combination with checkpoint inhibitors in metastatic cutaneous melanoma patients who previously received anti-PD(L)1 therapy. In this population with poor prognosis, and which is an unmet need, treatment with tebentafusp in combination with checkpoints resulted in a 76% one-year overall survival rate" said David Berman, Head of Research and Development at Immunocore.

In a new analysis of baseline gp100 protein expression by immunohistochemistry of tumor biopsies from the Phase 2 and Phase 3 tebentafusp monotherapy mUM trials, OS benefit was observed for both high and low gp100 protein tumor expression. Additionally, circulating tumor DNA (ctDNA) reductions were also observed for both high and low gp100 protein tumor expression, while high gp100 expression at baseline was associated with greater T cell infiltration into the tumor and greater IFNg, granzyme B and perforin expression.

"We are encouraged that the survival benefit from tebentafusp in metastatic uveal melanoma was independent of baseline gp100 tumor expression in this new analysis based on immunohistochemistry. This benefit, apparent even in patients with low gp100 protein expression, may reflect the high sensitivity of our TCR bispecific platform, which may be able to recognize cancer cells with very low target expression" said David Berman.

POSTER PRESENTATIONS

Title: Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels

Poster #: 868
Author: Emma Leach
Location: Poster Hall (Hall E)
Date & Time: November 13th – 12:30-2:00 pm and 7:00-8:30 pm ET
Title: Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma

Poster #: 546
Author: Omid Hamid
Location: Poster Hall (Hall E)
Date & Time: November 13th – 12:30-2:00 pm and 7:00-8:30 pm ET
Title: Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp

Poster #: 538
Author: Joseph J. Sacco
Title: Selective affinity-enhanced T cell receptor bispecific targeting of KRASG12D neoantigen driven cancers

Poster #: 882
Author: Andrew Poole
Location: Poster Hall (Hall E)
Date & Time: November 13th – 12:30-2:00 pm and 7:00-8:30 pm ET
Title: IL-2 Combination with ImmTAC Overcomes CD163+ Macrophage Inhibition of Redirected T Cell Killing of Tumour Cells

Poster #: 571
Author: Esra Güç
Location: Poster Hall (Hall E)
Date & Time: November 12th – 12:40-2:10 pm and 7:00-8:30 pm ET
Title: Radiomic Markers Associated with Clinical Benefit in Advanced Uveal Melanoma Patients with Radiographic Progression on Tebentafusp

Poster #: 819
Author: Volkan Beylergil
Virtual ePosters presented at the conference will be made available throughout the SITC (Free SITC Whitepaper) 36th Annual Meeting on the SITC (Free SITC Whitepaper) website.